Gsk (GLAXF) Retained Earnings (2009 - 2026)

Gsk's Retained Earnings history runs 18 years deep, the most recent figure standing at $1.9 billion for Q1 2026.

• In Q1 2026, Retained Earnings rose 48.09% year-over-year to $1.9 billion; the TTM figure through Mar 2026 stood at $1.9 billion (up 48.09% YoY), while the FY2025 annual figure was $1.7 billion, down 82.52% from the prior year.
• Retained Earnings was $1.9 billion for Q1 2026 at Gsk, up from $1.8 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $10.0 billion in Q4 2024 to a low of $1.2 billion in Q2 2024.
• Historically, Retained Earnings has averaged $2.3 billion across 5 years, with a median of $1.8 billion in 2025.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings surged 278.68% in 2024, then slumped 82.44% in 2025.
• A 5-year view of Retained Earnings shows it stood at $1.7 billion in 2022, then soared by 55.58% to $2.6 billion in 2023, then soared by 278.68% to $10.0 billion in 2024, then tumbled by 82.44% to $1.8 billion in 2025, then increased by 7.95% to $1.9 billion in 2026.
• The last three Retained Earnings figures came in at $1.9 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.8 billion (Q3 2025), per Business Quant data.